Companies › Sumitomo Pharma America
5 active drug programs in 5 registered trials: 5 Phase 1; Oncology, Neurology, Ophthalmology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Nuvisertib (TP-3654) PIM kinase inhibitor | PIM1, PIM2, PIM3 | Phase 1 | Myelofibrosis | Apr 2027 |
| Enzomenib (DSP-5336) Menin inhibitor | MEN1 | Phase 1 | Leukemia, Myeloid, Acute | Jun 2027 |
| DSP-3077 Retinal Sheet Retinal cell therapy (photoreceptor replacement) | – | Phase 1 | Retinitis Pigmentosa | Oct 2028 |
| SMP-3124LP Liposomal encapsulation formulation of SMP-3124 | – | Phase 1 | Solid Tumor | Dec 2028 |
| DSP-1083 Cell implant | – | Phase 1 | Parkinson's Disease | Dec 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04176198 | Nuvisertib (TP-3654) | Phase 1 | Myelofibrosis | Oncology | Apr 2027 |
| NCT04988555 | Enzomenib (DSP-5336) | Phase 1 | Leukemia, Myeloid, Acute | Oncology | Jun 2027 |
| NCT06891885 | DSP-3077 Retinal Sheet | Phase 1 | Retinitis Pigmentosa | Ophthalmology | Oct 2028 |
| NCT06526819 | SMP-3124LP | Phase 1 | Solid Tumor | Oncology | Dec 2028 |
| NCT06753331 | DSP-1083 | Phase 1 | Parkinson's Disease | Neurology | Dec 2030 |
Ryvu Therapeutics Biomea Fusion Kura Oncology Syndax Pharmaceuticals Johnson & Johnson (Janssen)
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.